Clinical Trial Update: CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

This clinical trial update reports on a Phase 1 study of a CD19-CD22 bispecific CAR-T cell therapy for pediatric acute lymphoblastic leukemia, currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19-CD22-bispecific CAR-T cell therapy

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Status: RECRUITING